Cargando…

CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas

Detalles Bibliográficos
Autores principales:	Hickman, Richard A., Gedvilaite, Erika, Ptashkin, Ryan, Reiner, Anne S., Cimera, Robert, Nandakumar, Subhiksha, Price, Adam, Vanderbilt, Chad, Fahy, Tara, Young, Robert J., Miller, Alexandra M., Mellinghoff, Ingo K., Rosenblum, Marc K., Ladanyi, Marc, Arcila, Maria E., Zhang, Yanming, Brannon, A. Rose, Bale, Tejus A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628020/ https://www.ncbi.nlm.nih.gov/pubmed/37831210 http://dx.doi.org/10.1007/s00401-023-02639-0

Ejemplares similares

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas
por: Huse, Jason T., et al.
Publicado: (2011)

The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low‐grade gliomas and glioneuronal tumors
por: Bale, Tejus A., et al.
Publicado: (2022)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma
por: Cagney, Daniel N, et al.
Publicado: (2019)

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
por: Yuile, Alexander, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
por: Hsu, Eric J., et al.
Publicado: (2022)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Genetic Alteration Analysis of IDH1, IDH2, CDKN2A, MYB and MYBL1 in Pediatric Low-Grade Gliomas
por: Barinfeld, Orit, et al.
Publicado: (2022)

Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas
por: Mäkelä, Katri, et al.
Publicado: (2014)

MPC-07 MECHANISMS OF BETTER PROGNOSIS IN IDH-MUTATED ASTROCYTOMA WITH 19Q-LOSS
por: Otani, Ryohei, et al.
Publicado: (2019)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history
por: Chan, Andrew K., et al.
Publicado: (2017)

Adverse Histology, Homozygous Loss of CDKN2A/B, and Complex Genomic Alterations in Locally Advanced / Metastatic Renal Mucinous Tubular and Spindle Cell Carcinoma
por: Yang, Chen, et al.
Publicado: (2020)

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
por: Huang, L. Eric
Publicado: (2022)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

FGFR- gene family alterations in low-grade neuroepithelial tumors
por: Bale, Tejus A.
Publicado: (2020)

IDH‐mutated astrocytomas with 19q‐loss constitute a subgroup that confers better prognosis
por: Otani, Ryohei, et al.
Publicado: (2018)

MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
por: Otani, Ryohei, et al.
Publicado: (2020)

PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS
por: Bornhorst, Miriam, et al.
Publicado: (2020)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

NI-1 METHYLTHIOADENOSINE PHOSPHOLYLASE STATUS CORRELATES WITH PROGNOSIS AND METHIONINE UPTAKE IN IDH MUTANT ASTROCYTOMA
por: Yamamura, Toshihiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_up5pm528n1scdnjsjo9k3jnpul